MacroGenics is a biotechnology company developing immunotherapeutics to prevent autoimmune disorders, cancer and infectious diseases.
MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases.The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology.The company was founded in 2000 and is headquartered in Rockville, Maryland.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 15, 2010 | Grant | $9.80M | 1 | National Institutes of Health | — | Detail |
Oct 23, 2008 | Series D | $25M | 3 | — | — | Detail |
Jul 29, 2008 | Series D | $12.50M | 1 | — | — | Detail |
May 17, 2006 | Series C | $45M | 1 | — | — | Detail |
Oct 15, 2004 | Series B | $30.50M | 3 | TPG | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | Yes | Grant |
TPG | — | Series D |
CIDC Consultants | — | Series D |
Innovis Investments | — | Series D |
Cogene Ventures | — | Series B |
Hunt Ventures | — | Series B |